
A vaccine for recurrent UTIs significantly reduced UTI episodes and a need for health care resources, reducing “the personal burden” of disease, according to researchers.
J. Curtis Nickel, MD, FRCSC, Emeritus Professor of Urology and Canada Research Chair in Urologic Pain and Inflammation at Queen’s University, presented data on the polybacterial sublingual vaccine MV140 (Inmunotek) at the American Urological Association Annual Conference.
“This vaccine … is going to be a game changer in patients with recurrent and chronic cystitis symptoms,” he said.
In the